AGP Picks
View all

Get your fresh news on health and wellness in New Hampshire

Provided by AGP

New Hampshire Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.

Press releases published on May 13, 2026

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
Verano Submits DEA Registration Applications for State-Licensed Medical Cannabis Businesses Following Landmark Federal Rescheduling Order 
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Seer Files Patent Infringement Lawsuit Against Nanomics
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Andera Partners Leads $20 Million Series D Financing in Rivermark Medical
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

Share us

on your social networks:

Sign up for:

New Hampshire Health Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.